DeLLphi-315 is a Phase 3 clinical trial studying tarlatamab, an investigational treatment, in extensive-stage small cell lung cancer (ES-SCLC). The study is comparing tarlatamab given as an injection under the skin with tarlatamab given through a vein to learn how safe and effective each method is. Study participants will be assigned to receive tarlatamab either under the skin (SC) or through a vein (IV).
Talk to an Amgen Medical Information Healthcare Professional to see if you qualify.
Patients who are 18 years or older
Small-cell lung cancer (SCLC) diagnosis was confirmed by tumor sample under a microscope
ES-SCLC with demonstrated radiographic progression or relapse after only 1 platinum-based chemotherapy regimen with or without anti-PD-(L)1 therapies
Participants with untreated asymptomatic brain metastases or those with treated stable brain metastases are allowed
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
Step 1: Screening
At your first visit(s), you will:
*This may not be needed in all cases. Your doctor will let you know if this is not needed.
If you meet the requirements and decide to join this clinical trial, you will move on to Step 2.
Step 2: Treatment
Approximately 400 participants will be randomly assigned to receive tarlatamab SC (Investigation drug) or tarlatamab IV (Control group).
The tarlatamab SC group:
The tarlatamab IV group:
You will continue receiving study treatment based on an ongoing evaluation of your overall health and response to the study treatment. This decision will be guided by the results of your blood tests, any side effects you may experience, and the findings from your imaging assessments. Your study doctor will review this information regularly to determine whether it is appropriate and safe for you to remain on study treatment and to ensure that the treatment continues to provide potential benefit.
Step 3: End of treatment
You will continue to receive treatment in this clinical trial based on the results of your bloodwork and imaging. You will continue receiving treatment based on the results of your blood tests, side effects you may experience, and imaging. The treatment you receive in this clinical trial may end if:
The Investigator site staff will schedule a follow-up visit with you approximately 9 weeks after your last trial treatment.
Step 4: Long term follow-up (up to 3 years)
The Investigator site staff may follow-up with you by phone or ask you to visit the clinic approximately once every 12 weeks.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.